1st Drug to Delay Type 1 Diabetes Approved by FDA

The first drug to delay the onset of type 1 Diabetes in those almost certain to develop the autoimmune disease has been approved by the United States Food and Drug Administration (FDA), the federal agency announcement (opens in a new tab) Thursday (November 17).

In type 1 diabetes, the immune system gradually eliminates insulin-producing cells, called beta cells. The new treatment, called teplizumab-mzwv (brand name Tzield), is a lab-made protein that behaves like a antibody produced by the human immune system. Once in the body, the so-called monoclonal antibody locks onto immune cells called T cells and reprograms them so they don’t aggressively attack beta cells in the pancreas, according to a statement from the drugmaker. ProventionBio. (opens in a new tab) At the same time, it increases the number of immune cells that thwart these attacks.

Leave a Reply

Your email address will not be published. Required fields are marked *